Faculty of Pharmacy, S. Sinha College, Aurangabad-824101, Bihar, India.
Department of Pharmaceutical Sciences and technology, Birla Institute of Technology, Mesra, Ranchi 835215, Jharkhand, India.
Curr Drug Deliv. 2019;16(5):400-429. doi: 10.2174/1567201816666190201144815.
In spite of advances in tuberculosis (TB) chemotherapy, TB is still airborne deadly disorder as a major issue of health concern worldwide today. Extensive researches have been focused to develop novel drug delivery systems to shorten the lengthy therapy approaches, prevention of relapses, reducing dose-related toxicities and to rectify technologically related drawbacks of anti-tubercular drugs. Moreover, the rapid emergence of drug resistance, poor patient compliance due to negative therapeutic outcomes and intracellular survival of Mycobacterium highlighted to develop carrier with optimum effectiveness of the anti-tubercular drugs. This could be achieved by targeting and concentrating the drug on the infection reservoir of Mycobacterium. In this article, we briefly compiled the general aspects of Mycobacterium pathogenesis, disease treatment along with progressive updates in novel drug delivery carrier system to enhance therapeutic effects of drug and the high level of patient compliance. Recently developed several vaccines might be shortly available as reported by WHO.
尽管在结核病（TB）化学疗法方面取得了进展，但结核病仍然是一种通过空气传播的致命疾病，是当今全球关注的主要健康问题。为了缩短漫长的治疗方法、预防复发、减少与剂量相关的毒性并纠正抗结核药物的技术相关缺陷，已经进行了广泛的研究来开发新型药物传递系统。此外，由于治疗效果不佳导致的耐药性迅速出现、患者顺应性差以及分枝杆菌的细胞内存活，突出了开发具有最佳抗结核药物效果的载体的必要性。这可以通过靶向和集中药物在分枝杆菌的感染库来实现。在本文中，我们简要总结了分枝杆菌发病机制、疾病治疗的一般方面，以及新型药物传递载体系统的最新进展，以增强药物的治疗效果和提高患者的顺应性。最近开发的几种疫苗可能会根据世界卫生组织的报告很快上市。
